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Abstract
Alternative splicing involves differential exon selection of a gene transcript to generate mRNA and protein isoforms with
structural and functional diversity. Abnormal alternative splicing has been shown to be associated with malignant
phenotypes of cancer cells, such as chemo-resistance and invasive activity. Screening small molecules and drugs for
modulating RNA splicing in human hepatocellular carcinoma cell line Huh-7, we discovered that amiloride, distinct from
four pH-affecting amiloride analogues, could ‘‘normalize’’ the splicing of BCL-X, HIPK3 and RON/MISTR1 transcripts. Our
proteomic analyses of amiloride-treated cells detected hypo-phosphorylation of splicing factor SF2/ASF, and decreased
levels of SRp20 and two un-identified SR proteins. We further observed decreased phosphorylation of AKT, ERK1/2 and PP1,
and increased phosphorylation of p38 and JNK, suggesting that amiloride treatment down-regulates kinases and up-
regulates phosphatases in the signal pathways known to affect splicing factor protein phosphorylation. These amiloride
effects of ‘‘normalized’’ oncogenic RNA splicing and splicing factor hypo-phosphorylation were both abrogated by pre-
treatment with a PP1 inhibitor. Global exon array of amiloride-treated Huh-7 cells detected splicing pattern changes
involving 584 exons in 551 gene transcripts, many of which encode proteins playing key roles in ion transport, cellular
matrix formation, cytoskeleton remodeling, and genome maintenance. Cellular functional analyses revealed subsequent
invasion and migration defects, cell cycle disruption, cytokinesis impairment, and lethal DNA degradation in amiloride-
treated Huh-7 cells. Other human solid tumor and leukemic cells, but not a few normal cells, showed similar amiloride-
altered RNA splicing with devitalized consequence. This study thus provides mechanistic underpinnings for exploiting small
molecule modulation of RNA splicing for cancer therapeutics.
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Introduction
Proteome complexity is expanded by alternative splicing (AS), a
process involving differential exon inclusion or exclusion of the
same pre-mRNA molecules to produce various mRNA and
protein isoforms [1,2]. The AS process is controlled by two highly
conserved protein families: arginine/serine dipeptide repeats (SR)-
related proteins and heterogenous nuclear ribonucleoproteins
(hnRNP)-related proteins [3,4]. SR proteins contain a modular
bipartite structure including one or two RNA recognition motifs at
the N terminus and a RS domain rich in arginine/serine dipeptide
repeats at the C-terminus [5,6]. The function of the N-terminal
motifs in SR proteins involves sequence-specific binding to exonic
splicing exhancers. The C-terminal RS domain serves as a general
activation domain for splicing by linking to a heterogeneous RNA
binding motif [6]. SR proteins regulate the selection of AS sites,
which diverge from canonical splice sites, therefore promoting
inclusion or exclusion of alternative exons. On the other hand,
some hnRNPs, such as hnRNPA1, may antagonize the AS
function of SR proteins through binding to exonic splicing silencer
elements [7].
AS therefore regulates gene expression by generating discrete
protein isoforms involved in distinct functions of cellular events,
such as apoptosis, sex determination, axon guidance, cell
excitation, and cell contraction [8,9]. AS also plays a pivotal role
in the development of human hereditary disorders and cancer
[10,11,12,13,14]. Aberrant AS of proto-oncogenes and/or tumor
suppressor genes may contribute to cellular malignant phenotypes,
such as resistance to apoptosis, promotion of invasion and
metastasis, and stimulation of tumor angiogenesis [11,12,13,14].
Postulating that modulating these cancer-related genes could have
profound impact on their pathogenic activities, we have been
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e18643searching for small molecules or drugs with modulating effects on
AS. In this study, we have found that amiloride, a well-known
diuretic, can alter oncogenic AS in human hepatocellular
carcinoma Huh-7 cells as well as in several other human cancer
and leukemic cell lines, and hence explore the underlying
molecular and cellular mechanisms for possible therapeutic
implications.
Results
Amiloride ‘‘normalizes’’ the isoform RNA splicing of BCL-
X, HIPK3 and RON/MISTR1 in Huh-7 cells
It has recently become clear that unbalanced RNA splicing of
certain genes is associated with malignant properties of human
cancer cells [11,12,13], e.g., resistance to chemotherapy and
radiotherapy with BCL-X, onco-developmentally undifferentiated
state with HIPK3, and invasive metastatic potentials with RON/
MISTR1. In hepatocellular carcinoma Huh-7 cells, BCL-X is
alternatively spliced into anti-apoptotic large RNA isoform, BCL-
XL, more than pro-apoptotic small RNA isoform, BCL-XS [15];
HIPK3 is spliced into exon 11-excluded U (-) as well as exon 11-
included U (+) isoforms for interaction with Fas/FADD to
modulate apoptosis in the developmental process [16]; and
RON/MISTR1 is spliced into 5-kb full-length (flRON) RNA and
2-kb exon 11-excluded RON (sfRON) RNA isoforms, the latter of
which has been correlated with epithelial to mesenchymal
transition in cancer cell invasion and metastasis [17,18]. After
screening more than 500 small molecules and drugs, including
those in clinical use, we found that amiloride exerted a potent
effect on AS of these gene transcripts (Figure 1A). Huh-7 cells
treated with amiloride showed: (a) relative decrease of BCL-XL
and increase of BCL-XS RNA isoforms; (b) relative maintenance
of HIPK3 U (-) and decrease of HIPK3 U( +) isoforms; and (c)
decrease of both exon 11 (+) flRON and exon 11 (-) sfRON RNA
isoforms. Such effects of amiloride were dose- and time-
dependent, being detectable by 2 hours and marked after
24 hours of incubation with 0.5 mM of amiloride. These
observations suggested increased utilization of the upstream
alternative 59-splice site within exon 2 of BCL-X, increased exon
11 (U) exclusion of HIPK3, and decreased splicing complexes
formed for production of both RON/MISTR1 exon 11 (+) and
exon 11 (-) isoforms. Thus, amiloride could modulate the AS of
these three gene transcripts towards less malignant ‘‘normalized’’
patterns, similar to the normal ones in previous reports
[15,16,17,18].
Because amiloride is a prototype intracellular pH (pHi)
modulator drug, we examined four amiloride derivatives at
equivalent or greater pHi-affecting doses. We observed that these
derivatives induced no similar ‘‘normalizing’’ effects on BCL-X,
HIPK3, and RON/MISTR1 AS patterns in Huh-7 cells (Figure 1B).
By contrast, in a previous study [19] we observed that 5-(N-ehyl-
N-isopropyl) amiloride (EIPA) but not amiloride modulated AS by
Figure 1. Modification of splicing patterns of BCL-X, HIPK3 and RON gene transcripts by amiloride. RNA was extracted from Huh-7 cells
exposed to growth medium containing amiloride or other pHi modulator amiloride derivatives and examined for the oncogenic RNA alternative
splicing by RT-PCR, as described in Materials and Methods. Panel (A) shows that amiloride increased the use of upstream alternative 59-splice site
within exon 2 that yields the apoptotic BCL-XS isoform (upper row), increased the exon 11 (U exon) skipping of HIPK3 that increases the apoptotic
isoform (middle row), and slightly increased the exon 11 skipping of RON at 0.5 mM concentration (lower row). Panel (B) shows that splicing
patterns of the tested genes were not significantly affected by four amiloride derivatives, including 5-(N-ethyl-N-isopropyl)-amiloride or EIPA; 5-(N-
methyl-N-isobutyl)amiloride or MIBA; 5-(N,N-dimethyl)amiloride or DMA; and 5-(N,N-hexamethylene)amiloride or HMA, at equivalent concentrations
of pHi modulation.
doi:10.1371/journal.pone.0018643.g001
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hereditary spinal muscular atrophy cells. These paradoxical
observations demonstrate the complexities of AS mechanisms
and also suggest that the splicing site selection in BCL-X, HIPK3,
and RON/MISTR1 transcripts in amiloride-treated Huh-7 cells is
mediated through cell-specific splicing mechanism(s) rather than
simply intracellular pH change.
Proteomic detection of mostly hypo-phosphorylated
splicing factor SF2/ASF in the cytoplasm and nucleus of
amiloride-treated cells
As phosphorylation status of SR protein components in the AS
complexes is known to affect protein-protein interaction for the
splicing function, we next used 2D-gel electrophoresis to analyze
differential expression of serine-phosphorylated proteins. We
found more than ten proteins with quantitative changes after
amiloride treatment (Figure 2). Choosing seven of these protein
spots for proteomic identification by mass spectrometry (Table 1),
we found one of them to be ASF/SF2, a splicing factor known to
be involved in AS of the RON transcript [20]. To verify this
finding, we performed western blots of ASF/SF2 and found
markedly reduced ASF/SF2 phosphorylation in both the
cytoplasm and nucleus of amiloride-treated Huh-7 cells
(Figure 3A). Analysis of other protein constituents of the splicing
complexes (such as SRp20, hnRNPA1, hnRNPA2/B1, Sam68
and common SR proteins) showed that SRp20 and two un-
identified phosphorylated SR proteins were also reduced in the
cytoplasm and nucleus after amiloride treatment (Figure 3B).
These results imply that amiloride modulates the AS of BCL-X,
HIPK3, and RON/MISTR1 through hypo-phosphorylation of
ASF/SF2 and decreased expression of SRp20 and some other SR
proteins.
Amiloride down-regulates phosphorylation of AKT kinase
and PP1 phosphatase
Recent studies have shown that amiloride inhibits phosphory-
lation of kinases and phosphatases associated with the PI3K-AKT
pathway [21,22,23], and that AKT kinase and PP1 phosphatase
may regulate the activity of SR proteins [23,24,25,26,27,28]. We
therefore determined the effects of amiloride on the phosphory-
lated forms of Akt kinase and related phosphatases in Huh-7 cells.
Decreased levels of the Ser(473) p-AKT and the Thr(320) p-PP1
were observed in the cytoplasm and nucleus, suggesting inhibition
of AKT kinase activity and activation of PP1 phosphatase activity
(Figure 4A). To determine whether inactivation of Akt kinase per
se would play a role in regulating the alternative splicing, Huh7
cells were treated with PI3K-AKT pathway inhibitors, including
LY294002, wortmannin and triciribine; 1 mM triciribine but not
LY294002 or wortmannin decreased the level of p-Akt. However,
triciribine at this concentration exerted no effect on the alternative
splicing of BCL-X and HIPK3 transcripts (Figure S1). Interestingly,
pre-treatment of the cells with okadaic acid to inhibit PP1
phosphatase activity abrogated the effects of amiloride on BCL-X
and HIPK3 splicing, as well as effects of amiloride on the
dephosphorylation of SF2/ASF and decreasing of the SRp20 level,
but okadaic acid exerted no definite effect on the expression of
hnRNP A1 and hnRNP A2B1 (Figure 4B). Taken together, these
results suggest that PP1 plays an important role in modulating
phosporylation of SR splicing factors and hence the modulation of
oncogenic AS in Huh-7 cells after amiloride treatment.
Figure 2. Amiloride effects on cellular phospho-serine proteins. 2D-gel electrophoresis analysis of proteins extracted from Huh-7 cells
without (left) and with (right) 0.5mM amiloride treatment for 24 hours showed significant changes for at least ten spots, of which seven (indicated by
arrows) were isolated for nano-LC-MS/MS spectrometry analysis and protein identification, as shown in Table 1.
doi:10.1371/journal.pone.0018643.g002
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PLoS ONE | www.plosone.org 3 June 2011 | Volume 6 | Issue 6 | e18643Figure 3. Effects of amiloride treatment on phosphorylation of SR-related proteins. Western blot analysis of subcellular fractions of Huh-7
cells with and without 0.5 mM amiloride 24-hour treatment was performed using specific antibodies against various splicing protein factors and b-
tubulin. (Panel A) The amiloride treatment increased the dephosphorylated SF2/ASF forms in both cytoplasmic and nuclear fractions. (Panel B) The
amiloride treatment decreased the expression of SRp20 and two un-identified phosphorylated SR proteins in both C (cytoplasmic) and N (nuclear)
cellular fractions.
doi:10.1371/journal.pone.0018643.g003
Table 1. Proteomic identification of 7 selected phosphoryl-serine proteins down- or up-regulated in amiloride-treated Huh-7 cells.
Spot
no.
Swissport
accession
no. Protein name
Mascot
score
Theoretical
PI/Mr(Da)
Sequence
coverage Unique peptides
Direction
of
regulation
1 07955 Splicing factor,
arginine/serine-rich 1
302 5.6/31,848 26%
17YVGNLPPDIR
27 26TKDIEDVFYK
37
51GGPPFAFVEFEDPR
64 74DGYDYDGYR
82 83LRVEFPR
89
122VVVSGLPPSGSWQDLK
137 154DGTGVVEFVR
163
Down
2 P25705 ATP synthase alpha chain,
mitochondrial precursor
216 9.1/59,174 13%
46TGTAEMSSILEER
58 50ILGADTSVDLEETGR
73
74VLSIGDGIAR
83 134TGAIVDVPVGEELLGR
149
150VVDALGNAIDGK
161 195AVDSLVPIGR
204
Down
3 P25705 ATP synthase alpha chain,
mitochondrial precursor
763 9.1/59,174 39%
45TGTAEMSSILEER
58 59ILGADTSVDLEETGR
73
74VLSIGDGIAR
83 89NVQAEEMVEFSSGLK
103
104GMSLNLEPDNVGVVVFGNDK
123
133RTGAIVDVPVGEELLGR
149
150VVDALGNAIDGKGPIGSK
167 183ISVREPMQTGIK
194
195AVDSLVPIGR
204 208ELIIGDR
214 219TSIAIDTIINQK
230
254STVAQLVK
261 306HALIIYDDLSK
316 323QMSLLLR
329
335EAYPGDVFYLHSR
347 403GIRPAINVGLSVSR
416
427QVAGTMKLELAQYR
441
Down
4 P70355 Annexin A2 627 7.5/38,449 39%
10LSLEGDHSTPPSAYGSVK
27 25AYTNFDAER
36
37DALNIETAIK
46 49GVDEVTIVNILTNR
62
68QDIAFAYQR
76 104TPAQYDASELK
114
152TDLEKDIISDTSGDFR
167 178RAEDGSVIDYEL-
IDQDAR
196 198DLYDAGVK
203 313SLYYYIQQDTK
323
Down
5 P32322 Pyrroline-5-carboxylate
reductase 1
477 7.1/33,340 47%
30IMASSPDMDLAITVSALRK
47 108LSAFRPAPR
118
120CMTNTPVVVR
129 130EGATVYATGTHAQVEDGR
147
205LGAQALLGAAK
215 216MLLHSEQHPGQLK
228
229DNVSSPGGATIHALHVLESGGFR
251
252SLLINAVEASCIR
264 267ELQSMADQEQVSPAAIKK
284
290VKLDSPAGTALSPSGHTK
307
Down
6 Q06830 Peroxiredoxin-1 266 8.2/22,096 41%
17ATAVMPDGQFK
27 28DISLSDYK
35
94QGGLGPMNIPLVSDPK
109 111TIAQDYGVLK
120
121ADEGISFR
128 129GLFIIDDK
136 141QITVNDLPVGR
151
159LVQAFQFTDK
168
Down
7 P19623 Spermidine synthase 176 5.3/33,803 17%
48YQDILVFR55
97VLIIGGGDGGVLR
109
136FLPGMAIGYSSSK
148 187ESYYQLMK
194
286AAFVLPEFAR
295
Up
doi:10.1371/journal.pone.0018643.t001
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splicing of many functional genes in amiloride-treated
cells
It is possible that the effects of amiloride on the phosphorylation
and intracellular localization of splicing factors and mRNA export
[29] could affect splicing of other gene transcripts in addition to
BCL-X, HIPK3 and RON/MISTR1. Using gene array chips
(Affymetrix GeneChipH Human Exon 1.0 ST Array of .518000
exons of 42974 genes) for exon array analysis (set parameters of
correlation coefficient $0.7, splicing index #21.585 , and log2
ratio #21.585), we found that amiloride influenced the splicing
patterns of 551 genes involving at least 584 exons, which included
495 known protein-coding genes involving 526 exons (Table S1;
MIAME accession number #GSE24581). These 495 known
protein-coding genes could be classified into functional categories
involving cytoskeleton remodeling, cell adhesion, ion transport,
transcription factors, immune response, and muscle contraction
(Figure 5A-C and Table S2). To verify these exon array results, we
selected seven (APF-1, CRK, MBNL2, MIZF, WAC, PAPDS and
survivin) for analysis by RT-PCR and indeed confirmed distinct AS
pattern alterations of these gene transcripts in amiloride-treated
cells (Figure 5D).
At detailed gene ontology (GO) levels, the RNA transcripts
showing amiloride-affected AS included: a). 4 of 5 genes (80.0%)
of ‘‘microfilament motor activity’’ (GO 0000146), and 28/132
(21.2%) of genes of ‘‘motor activity’’ (GO 0003774); b). 5 of 7
(71.4%) of ‘‘cation:chloride symporter activity’’ (GO 0015377), 5/
18 (27.8%) of ‘‘anion-cation symporter’’ (GO 0015296), 3/10
(30.0% ) of ‘‘sodium potassium exchanging ATPase’’ (GO
0005391), and 2/8 (25.0%) of inorganic anion exchange activity’’
(GO 0005452) ; c). 2 of 3 (66.7%) nitric- oxide synthase activity
(GO 0004517); d) 16/29 genes (62.1%) of ‘‘extracellular matrix
structural constituent conferring tensile strength’’ (GO 0030020),
38/346 genes (11.0%) of ‘‘cytoskeletal protein binding’’ (GO
0030020), 2/7 (28.6%) of collagen binding (GO 0005518); 2/8
(25.0%) of ‘‘myosin binding’’ (GO 0017022), and others. Of 213
apoptosis-related genes, 6 (CCAR1, EP3000, KIAA1967, PRKDC,
and PRPF8) showed altered alternative splicing by amiloride. Of
608 cancer-related genes, 32 including RON/MISTR1, ATM
(ataxia teleangiectasis mutated) and FANCM (Fanconi anemia M
protein) were affected by amiloride. As ATM plays an important
role in DNA damage repair while FANCM is involved in the
assembly of Fanc protein complexes that maintain genome
integrity and stability [30], altered AS of these two gene transcripts
by amiloride may result in chromatin degradation, as verified in
our subsequent experiments. However, RON/MISTR1, but not
BCL-X and HIPK3, was among the 495 genes detected to have
amiloride-altered splicing patterns by exon array analysis,
presumably because of the stringent quantitative criteria set,
and/or short spliced sequences of BCL-X.
Using known consensus nucleotide sequences of splicing
regulatory elements, we further identified possible splicing
enhancer and silencer elements in the alternative splicing exon,
59-flanking intron and 39-flanking intron regions of the 495 genes
affected by amiloride (Table S3). These splicing cis-elements are
the binding sites of ASF/SF2, SRp55 and other unknown
regulatory factors. During interactions of SF2/ASF and other
SR protein factors with cis-elements in the splicing complexes, the
functional state of protein-protein binding complexes may be
modulated by the phosphorylation status of the proteins
[21,23,31,32]. This implies that the altered splicing of these gene
transcripts was mediated through amiloride-induced hypo-phos-
phorylation of SF2/ASF and other SR proteins.
Decreased cell mobility/invasion activities and depleted
cytoskeletal structures following AS changes of involved
genes after amiloride exposure
Because altered RON/MISTR1 splicing mediated by SF2/ASF
has been shown to result in increased mobility and invasive
activities of cells [20], we examined the functional impact of
amiloride-induced decrease of exon 11 (+)f l RON and exon 11 (-)
sfRON isoforms (Figure 1C) and decrease of exon 13 and exon 20
inclusion detected by exon array analysis (Table S1). Migration of
cells from a scraped monolayer edge was impaired by 0.4 mM
amiloride (Figure 6A). Fluorescent phalloidin binding demonstrat-
ed alteration of F-actin cytoskeletal scaffolds from a peri-nuclear
Figure 4. Phosphorylation of Akt kinase (activation) and PP1 phosphatase (inactivation) in relation to amiloride-altered AS
mechanisms. (Panel A). Western blots show significant decreases of cytoplasmic p-Akt, nuclear p-Akt and nuclear p-PP1 in Huh-7 cells treated with
amiloride at 0.3 mM and above. (Panel B) RT-PCR and western blot analyses show that pre-treatment with a PP1 inhibitor, okadaic acid, abrogated
the amiloride effects on the BCL-X and HIPK3 oncogenic RNA splicing, the phosphorylation of ASF2/ASF splicing factor and the level of SRp20 in Huh-
7 cells.
doi:10.1371/journal.pone.0018643.g004
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an apparently rigid enclosure of multiple nuclei in amiloride-
treated cells, and also severe depletion of cytoplasmic contents,
including F-actin, after exposure to 0.4 mM or higher concentra-
tions of amiloride (Figure 6B). These observations of impaired cell
mobility and abnormal cytoplasmic organization of F-actin are
consistent with our exon array findings of altered RNA splicing of
many key interacting protein components of the extracellular
matrix, including collagen families for cytoskeletal networks as well
as myosin families and their binding proteins (Table S1), in
addition to RON/MSTIR and associated regulatory molecules.
Perturbation of cell cycle progression and mitotic
cytokinesis by amiloride
Our exon array analysis of amiloride-treated Huh-7 cells
(Tables S1 & S2) detected alterations of RNA splicing predom-
inantly of proteins involved in cytokinesis, associated with solute
transport, and functions of actin, microtubules, and cytokinesis-
related kinases [33]. In addition, the altered RNA splicing of
CENPE (centromere protein E 312kDa), CEP250 (centrosomal
protein 250kDa) and CEP192 (centrosomal protein 192kDa) would
be expected to result in inefficient chromatid separation during the
cell cycle. Indeed, proliferation of Huh-7 cells was inhibited by
0.3 mM amiloride or higher in the growth medium (Figure 7A).
Furthermore, there was an accumulation of G2/M tetraploid cells
beginning at 24 hours, becoming marked at 48 hours (Figure 7B).
By light microscopic examination, there were many bi-nucleated
and late-stage anaphase cells that were presumably the G2/M
tetraploid cell population observed by fluorocytometry. During
cell cycle progression and daughter cell separation in the presence
of varying concentrations of amiloride, mitotic cells exposed to
amiloride at 0.3 mM or higher developed into bi-nucleated forms
at 24 hours but subsequently failed to generate separated daughter
cells (Figure 6C and 6D). These three observations imply that
through altering the RNA AS of genes, amiloride causes
disturbance of cytokinesis by inhibiting mitotic cells from passing
through late anaphase processes of abscission, division, and
separation of daughter cells. Finally, we confirmed a previous
report that Huh-7 cells express Prominin/AC133/CD133, an
immunological marker of the ‘‘cancer stem-like’’ cells [34], and
further found that amiloride at 0.3 mM or more down-regulated
CD133 expression Huh-7 cells (Figure S2-A), resulting in
suppression of the number and size of cell colony formations
(Figure S2-B).
Cell death with severe DNA degradation subsequent to
amiloride-induced altered splicing of functional
molecules in apoptosis and DNA repair pathways
In amiloride-treated cells, splicing changes of BCL-X and HIPK3
RNAs (Figure 1A) would predict altered cellular apoptosis
mechanisms, and altered AS of ATM and FANCM RNAs (Table
S1) would alter DNA repair and cellular genome protection
mechanisms. Huh-7 cells culture in the presence of 0.3 to 0.5 mM
amiloride demonstrated not only lack of cell growth but also
subsequent loss of initially plated Huh-7 cells (Figure 7A).
Apoptosis was evident by increased percentages of annexinV
binding cells after exposure to 0.3–0.5 mM amiloride for 24 or
46 hours (Figure 7C). Furthermore, fluorocytometric analysis of
Figure 5. Gene ontology distribution of 495 protein-encoding gene transcripts with amiloride-modulated AS patterns in Huh-7
cells. Bioinformatic analyses of the 495 gene transcripts with amiloride-modified alternative splicing, detected by the genome-wide exon-array
measurements, were performed according to gene ontology categories of Biological Process (A), Molecular Function (B) and Cellular Component (C).
Amiloride-altered AS patterns of APAF1, CRK,MBNL2, MIZF,WAC, PAPD5 and SURVIVIN specific protein-encoding gene transcripts detected by the exon-
array analysis were validated by RT-PCR of spliced RNA isoforms (Panel D).
doi:10.1371/journal.pone.0018643.g005
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degradation in more cells than those demonstrated to be
undergoing apoptosis; after exposure to 0.4 mM amiloride, only
48.2%, 6.5%, and 1.2% of Huh-7 cells had intact cellular DNA
profiles after 24, 48, and 72 hours respectively (Figure 7D).
Similar modulating effects of amiloride on oncognic RNA
splicing in other human solid tumor and leukemic cell
lines
To determine the generality of amiloride effects observed in
Huh-7 cells, we used additional 10 established human cancer and
leukemia cell lines, including 2 hepatoma HepG2 and Hep3B;
rhabdomyosarcoma TE671; 3 glioblastoma multiforme 8401,
ASCG13T1xm and ASCG7T(4); 2 colon cancer invasive cell lines
HT29 and COH; and 3 leukemias K562, HL60 and Molt4 cells,
and a normal bone marrow-derived mesenchymal stromal line
KP-hMSC as well as a few normal blood lymphocyte cultures, to
perform various fore-mentioned experiments. Our results showed
that in general amiloride tended to affect the malignant
phenotype-associated AS more than the normal AS in the cell.
First, essentially as in Huh-7 cells (Figure 1), we found amiloride-
modulated ‘‘normalization’’ of the abornal BCL-X and HIPK3
Figure 6. Cell migration and post-mitotic cytokinesis disorders subsequent to amiloride-altered AS of related functional gene
transcripts. (Panel A). Cell migration was determined in confluent Huh-7 cell monolayers scraped with a plastic scraper, exposed to growth
medium with or without 0.45 mM amiloride for 48 hours, rinsed 2x with PBS and onward fed growth medium without amiloride. Serial microscopic
photographs of same areas (marked green or red on the bottom side of dishes) taken at 48 and 96 hours show complete inhibition of cell migration
from the edge of amiloride-treated monolayer. (Panel B) Cells exposed to the indicated concentrations of amiloride in growth medium for 36 hours
were fixed with paraformaldehyde, permealized and stained with DAPI and FITC-phalloidin for observation by confocal microscopy. DAPI-stained
nuclei are magenta-pseudocolored in merged confocal photographs. (Panel C) Inhibitory effect of amiloride on cytokinesis was observed with
mitotic Huh-7 cells shaken off from the dish, re-plated in growth medium containing different concentrations of amiloride. The dividing daughter
cells were fixed at 24, 48 and 72 hours, stained and photographed microscopically. (Panel D) Measurement of distances between the two nuclei of
dividing or divided daughter cells shows that amiloride inhibits post-mitotic cytokinesis and separation of daughter cells. The diameter of the cell
nucleus is set as 10. The average and standard deviation of each sample point are from 15 to 20 daughter cell pairs.
doi:10.1371/journal.pone.0018643.g006
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TE671, glioblastoma 8401, leukemias K562, HL60 and Molt4
(e.g. supplementary data of [35]). Most significantly, amiloride
could modulate the transcription/splicing of BCR-ABL fusion gene
and re-sensitize the chemoresistant Bcr-AblT3151 mutant cells to
imatinib [35]. On the contrary, using amiloride up to 2 mM in the
growth medium, we detected no alteration in the BCL-X and
HIPK3 splicing patterns in cultured activated normal peripheral
blood mononuclear cells (supplementary data of [35]) nor in
immortalized bone marrow stromal KP-hMSC cells. Consistently,
amiloride in the range of 0.02 mM-0.5 mM was cytotoxic to
cancer cells but not to normal cells in culture (Figure S3 A & B).
Using a 72-hour in vitro culture assay, we found that the 50%
growth inhibiting doses of amiloride were approximately 0.02 mM
for TE671, 0.10 mM for K562, 0.20 mM for Huh-7, 0.3 mM for
two other HCC Hep-G2 and Hep-3B, and 0.2–0.4 mM for the
three glioblastoma multiforme lines but .3 mM or unmeasurable
for the normal cell lines (Figure. S3-B). Further, we performed
global exon array analysis on myeloid leukemia blasts K562 and
glioblastoma 8401, with and without amiloride treatment, for
comparison with Huh-7 (Tables S1, S2 and S3). Cross-matching of
the 200 top-scored amiloride-modulated genes of each of the three
cell lines revealed a rather common feature of amiloride-
modulated splicing, namely that 187 genes or 93.5% of these
200 were the same for the three cells; 188 (187 plus DNAH8) for
Huh-7 and 8401; 189 (187 plus LRP2/RYR2) for Huh-7 and
K562; and 190 (187 plus ABL1, ColSA2, NAALAD2) for 8401 and
A549 (Figure S4-A). The GO analysis of the 187 common genes
according to the biological processes (Figure S4-B), molecular
functions (Figure S4-C) and cell components (Figure S4-D)
categories showed percentage distribution similar to the amilo-
ride-modulated 495 genes of Huh-7 cells (Figure 5), implying that,
Figure 7. Growth inhibitory and apoptotic/cytotoxic consequences of amiloride-induced AS alterations. (Panel A) Huh-7 cells plated in
6-well dishes at 3610
5 cells per well overnight were changed to growth medium containing various concentrations of amiloride; cell numbers were
determined one and three days later. Cell counts at 24 hours show growth inhibition by amiloride at 0.4 mM and above. Further cell count decreases
were evident at 72 hours due to cell death and detachment in medium containing amiloride at 0.3 mM and above. (Panel B) Cytofluorometric
analysis shows amiloride inhibition of cell cycle progression with accumulation of G2/M phase cells. (Panel C) Apoptosis is evident by
cytofluorometric detection of annexinV binding in Huh-7 cells treated with 0.5 mM of amiloride. (Panel D) Marked nuclear DNA degradation was
observed in Huh-7 cells treated with 0.4 mM amiloride but not with 0.2 mM amiloride, particularly noted at 48 and 72 hours.
doi:10.1371/journal.pone.0018643.g007
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causes similar effects on the cytoskeletal structure, cytokinesis, and
DNA repair, as well as on the apoptosis mechanism and the solute
transport system.
Discussion
This study is based on our initial finding that amiloride changed
the alternative RNA splicing of BCL-X, HIPK3 and RON/MISTR1
transcripts from oncogenic patterns towards normal patterns in
human hepatocellular carcinoma Huh-7 cells. In follow-up
experiments, we observed hypo-phosphorylation of SR splicing
factors, especially SF2/ASF, as well as in upstream protein kinases
and phosphatases, suggesting that amiloride may affect the
functional state of exon inclusion/exclusion complexes. Global
exon analysis indeed revealed alterations of AS in many gene
transcripts of cellular networks. As a consequence, amiloride-
treated Huh-7 cells showed decreased migration/invasion cytoki-
netic capabilities, retarded cell cycle progression with mitotic
defects, increased apoptotic signs, severe cellular DNA damages
and ultimate cell death. Exploring subsequently, we have now
obtained results that amiloride treatment can produce similar AS
modulation and devitalizing effects on several other human
malignant solid cancers and leukemic cell lines in addition to
hepatocellular carcinoma Huh-7, but apparently not on a few
cultured normal cells we tested (Figures S3 and S4).
A distinct property of amiloride in modulating AS-
mediated malignant phenotypes
Amiloride, 3,5-diamino-6-chloro-N-(diaminomethylene) pyrazi-
necarboxamide monohydrochloride, was developed in the 1960’s
[36] and has been a drug used clinically for treating edema and
hypertension based on its sodium transport and fluid homeostasis
effects [37]. Therefore, we initially thought that its effects on
oncogenic RNA splicing would be mediated by changes in
intracellular pH and ion movement. However, no similar AS
alterations were detected in Huh-7 cells treated with four more
potent pHi-affecting amiloride analogues, including EIPA, which
we previously showed to modulate the pathogenic SMN2 transcript
in cells of spinal muscular atrophy patients. Thus, the ability to
alter AS of oncogenic RNAs appears to be a distinct property of
amiloride.
As AS is controlled by highly conserved SR family proteins
[1,3,5] and plays an important role in the proteomic complexity of
the cell, it is of interest to determine whether this property of
amiloride is applicable to various other human malignant cancer
types and abnormal cells with altered AS of various genes. In
subsequent investigations, we have found that amiloride exerts
very similar if not common effects on AS of cellular gene
transcripts in the diverse context of malignant cell types examined.
For example, in myelogenous blasts K562, amiloride not only
‘‘normalized’’ the abonormal BCL-X and HIPK3 splicing but also
modulated the alternate splicing of BCR-ABL transcript and re-
sensitized the chemoresistant Bcr-AblT3151 mutant cells to
imatinib [35].
Mechanism of AS alterations by amiloride
By inference from a previous report [20], our observation of
hypo-phosphorylation of SR protein splicing factors, particularly
SF2/ASF and SRp20, may explain the modified alternative
splicing of RON/MSTIR in amiloride-treated cells. SR proteins are
nuclear phosphoproteins localized to nuclear speckles [6]. The RS
domain of SR proteins determines the subcellular localization by
acting as a nuclear localization signal in interaction with the
transportin-SR, a nuclear import receptor for SR proteins [38].
The extensive serine phosphorylation of the RS domain is also
important for regulating the activities and localization of SR
proteins [39]. Protein kinases involved in the phosphorylation or
dephosphorylation of SR-related proteins have been found to
affect nuclear location of SR proteins and hence regulation of AS
[39,40]. Our finding of un-phosphorylated and hypo-phosphory-
lated ASF/SF2 in amiloride-treated cancer cells therefore
implicates the inhibition of protein kinases or stimulation of
protein phosphatases. It has been well documented that amiloride
can inhibit the activities of tyrosine kinase, serine kinase and
phosphatase through non-specific kinase inhibition [22,24,25,
26,27,28]. Amiloride-mediated inhibition of kinases can be
relieved by their ATP substrate with kinetics of competitive
inhibition [41]; however, the possibility of amiloride directly acting
as an ATP substrate inhibitor in kinase reactions, thus causing SR
protein hypo-phosphorylation, remains to be investigated. On the
other hand, we have confirmed previous reports that amiloride
can inhibit or alter the phosphorylation of key molecules in the
PI3K-AKT pathway [22]. AKT has been reported to regulate the
activity of SR proteins [24,27]; and there are several consensus
motifs for AKT phosphorylation in the RS domain of SR proteins.
However, we were unable to alter the oncogenic RNA splicing of
BCL-X and HIPK3 by chemical inhibitors of the PI3K-AKT
pathway (Figure S1). However, we found that pre-treatment with
okadaic acid, a PP1 inhibitor, did abrogate the amiloride-altered
splicing of RON and HIPK3 transcripts as well as preventing the
hypo-phosphorylation of ASF/SF2 and SRP20 SR proteins
(Figure 4). We further found that amiloride decreased the
phosphorylation of ERK 1 and 2, PPI phosphatase, but caused
up-regulation of phosphorylation of P38 and JNK. It remains to be
determined definitively whether or not and how these signaling
pathways would mediate the amiloride effects in modulating RNA
splicing processes by affecting protein phosphorylation of AS
regulatory factors.
Global proteo-genomic approaches to explore drug
targeting of AS modifications
Regulatory mechanisms of AS have been most commonly
explored by using cis-element-containing minigenes and/or
transfected trans-acting recombinant SR factors and related
regulatory proteins. Nevertheless, with the recent estimate that
AS may occur in RNA transcripts from 74 - 88% of human genes
[42,43], pursuit at a global level would be required to elucidate the
physiological and/or pathological significance of altered AS and
the correlated regulatory networks. Many prior studies of the
cellular and molecular biology of cancer have reported the
occurrence of aberrant AS of important regulatory genes without
mutation; however, genome-wide analyses of aberrant AS in
various cancer phenotypes, including tumor initiation and
malignant progression, remains incomplete [43]. In this study of
the Huh-7 cell model of human cancer, we initially exploited
known ‘‘oncogenic’’ AS and then used a combination of
biochemical, proteomic, genomic and bioinformatic approaches
to address pertinent questions of drug modulation in terms of the
AS mechanisms. The 2-dimensional gel blotting and proteomic
techniques were able to elucidate drug-induced serine phosphor-
ylation changes of SR proteins and related factors. The use of exon
array data for computational nucleotide sequence search within
the exons and their59 and 39 flanking introns, further defined the
location and degeneracy of binding and splicing site selection by
individual regulatory factors (Table S3). However, this approach
could determine only the steady-state AS isoforms at a fixed 24-
hour time-point but not kinetic changes, thus was likely to miss AS
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certain databases, ATM and FANC-M were annotated with DNA
repair function but not listed in this gene ontology category.
Despite these minor technical complications, the combined exon
array and computational analysis proved better than prospective
biochemical analysis to assess and predict the cellular biology
outcome of amiloride-treated Huh-7 cells. This approach
demonstrated that more extensive cell death in addition to
apoptosis occurred as a consequence of modified AS of DNA
repair protein factors, in addition to anti-apoptosis factors like
BCL-XL isoform (Figure 7).
Modification of AS in many cytoskeletal network genes in
addition to RON also explains the marked inhibition of invasive
activity and cell cycle cytokinesis (Figure 6). Perhaps most
significantly, the present approach revealed that amiloride could
affect the AS of some genes (Tables S1 & S2), such as ATM and
FANCM, mutation of which is associated with leukemogenesis.
Our additional exon array experiments indicated that many, if not
most, of the amiloride-affected 495 known protein-coding mRNAs
in Huh cells were also modulated by amiloride in another human
solid tumor and a leukemic cell line (Fig. S4). It would be of
interest to investigate if any of the 187 genes commonly modulated
by amiloride in Huh-7, A549 and 8401 cells would participate in
the development of the malignant properties and thus could be
exploited as target(s) for drug discovery. As to the question
whether or not the in vitro amiloride effects found in this study
could be reproduced in vivo for direct cancer therapy, it should be
noted that the 0.02 mM to 0.5 mM amiloride concentrations,
which could alter oncogenic RNA splicing to devitalize to human
cancer cells but not some human normal cells we tested, are 1- to
3-order higher than peripheral blood plasma levels achieved by
doses of amiloride administered clinically for anti-hypertensive
purpose. Systemic animal tumor model studies with pharmaco-
logical approaches and further translational research would be
worthwhile to address these critical problems concerning clinical
application of amiloride for cancer therapy.
Materials and Methods
Cell culture and drug treatment
Huh-7 human hepatocellular carcinoma (HCC) cell line, Huh-
7, was purchased through Food Industry Research and Develop-
ment Institute (Hsinchu, Taiwan). Other established cell lines
originally from ATCC (Rockville, MD) were HCC HepG2
(HB8065) and Hep3B (HB8064), colon cancer HT29 (HTB-38)
Inv3 clone [44], promyeolocytic leukemia HL60 (CCL-240) and
acute lymphoblastic leukemia Molt4 (CRL-1582). Two lines of
glioblastoma multiforme, ASCG13T1xm and ASCG7T-4, and a
liver-metastatic colon cancer line COW[45] of Chinese patients’
origin were established by one of us (DMY). Our stocks of chronic
myeloid blasts K562[46], glioblastoma multiforme 8401[47] and a
normal bone marrow mesenchymal cell line KP-hMSC[48] were
from original investigators, the late Dr. Bismark Lozzio, Dr.Harn
and one of us (WKY), respectively. Rhabdomyosarcoma cell
line,TE671, was from Dr. LJ Chang (University of Florida).
The monolayer of Huh-7 cells was grown in DMEM, other
solid tumor monolayers in MEM and leukemic cell suspension in
RPMI-1640 (plus 0.05 mM mercaptoethanol), all supplemented
with 10% FBS, 100 U/ml penicillin, and 100 mg/ml streptomycin
(Invitrogen Inc, USA), and maintained at 37uC in a humidified
5% CO2 incubator. All chemical reagents including amiloride,
amiloride derivatives, okadaic acid, AKT pathway inhibitors and
cell culture grade anhydride DMSO were obtained from Sigma
Chemical Co., USA. Stock solution of amiloride (250 mM) was
prepared in DMSO. For dose response experiments, we treated
cells (1x10
6/ml plated on a 100-mm dish overnight) with various
concentrations of drugs in the growth medium for 24 hours. For
kinetic studies, we added 0.5 mM amiloride to the medium and
harvested the cells at various time points.
RNA isolation, reverse transcription and PCR
amplification (RT-PCR)
RNA isolation from cultured cells and RT-PCR analysis were
performed as described [19,49]. For analysis of BCL-X, HIPK3 U-
exon, and RON alternatively spliced mRNA isoforms, PCR was
performed with the following primer pairs:
BCL-X forward, 59-GAGGCAGGCGACGAGTTTGAA-39,
BCL-X reverse, 59-TGGGAGGGTAGAGTGGATGGT-39;
HIPK3 forward, 59-AGCCTGCCACTACCAAGAAA-39,
HIPK3 reverse, 59-CAGCAATTTCTTGCCTCTCC-39;
RON forward, 59-GATGGAGCTGCTGGCTTTAC-39,
RON reverse, 59-ATACCAAGGAGCGTGCTCTG-39.
The PCR was performed with a denaturing step at 94uC for 5
minutes, then 35 cycles of 30 seconds at 94uC, 30 seconds at 56uC
(BCL-X), 58uC( HIPK3 u-exon), or 54uC( RON) and 1 minute at
72uC, followed by a final 5 minutes at 72uC. The PCR products
were separated on 2.5% agarose gel and the intensity of the PCR
products were analyzed by LabWorks Image Acquisition and
Analysis Software (UVP BioImaging Systems). DNA gel bands of
these RT-PCR products were isolated for sequencing to verify the
authenticity of spliced isoforms.
Protein extracts and Western blotting
The cytoplasmic and nuclear fractions of cells were isolated by
using NE-PER Reagent (Pierce Inc., USA) as described previously
[49]. Total protein extracts were isolated by using a lysis buffer
solution containing 50 mM Tris-HCl (pH 7.5), 137 mM sodium
chloride, 1 mM EDTA, 1% Nonidet P-40, 10% glycerol, 0.1 mM
sodium orthovanadate, 10 mM sodium pyrophosphate, 20 mM b-
glycerophosphate, 50 mM sodium fluoride, 1 mM phenylmethyl-
sulfonyl fluoride, 2 mM leupeptin, and 2 mg/ml aprotinin. The
protein samples were separated by SDS-PAGE and then
transferred to polyvinylidene fluoride membranes (Millipore).
The membrane was blocked wi th 5% BSA and then exposed to
the appropriate concentrations of primary antibodies at 4uC
overnight, followed by horseradish peroxidase-conjugated second-
ary antibody for detection by enzyme chemiluminescence kit
(Amersham Inc., USA). Intensity of the signals was measured by
using the LabWorks software (UVP BioImaging Systems).
Proteomic analysis of serine phosphorylation proteins
100 mg of protein extracts were mixed with sample buffer,
which contained 9M urea, 0.5%(v/v) Triton X100, 10 mM DTT,
0.01% (w/v) bromophenol bule, and 2% (v/v) pH 3–10
ampholytes, and incubated for 30 minutes at 37uC; insoluble
material was removed by centrifugation at 14,000 rpm for 10
minutes at 25uC. First-dimensional IEF was performed at 20uCi n
13-cm immobilized pI 3–10 linear gradient strips at 50 mA/strip
and for 24,500 V/h using the IPGphor system (Amersham
Biosciences). The strips were first rehydrated for 6 hours at
25uC in rehydration buffer containing 8M urea, 0.5%(v/v) Triton
X100, 10 mM DTT, 0.01% (w/v) Orange G, and 0.5% (v/v)
pH 3–10 ampholytes. After focusing, the strips were immediately
equilibrated for 15 minutes at 25uC with gentle shaking in 10 ml
of 50 mM Tris-HCl (pH 8.8), 6 M urea, 50% (w/v) glycerol, 2%
(w/v) SDS, and 0.01% (w/v) bromophenol blue. The second
dimension electrophoresis was performed on 12.5% SDS gels in a
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performed western blot with anti-phosphoserine antibody and
recorded the signal intensity by using the LabWorks software.
Computerized 2-D gel analysis (spot detection, spot editing,
pattern matching, and data analysis) was performed using the
ImageMasterTM Platinum v5.0 software package. Protein spot
changes showing increase or decrease of .50 % in magnitude
were scored between the treated and the control sample pair.
Mass spectrometry and protein identification
Protein spots were excised from preparative gels with a pipette
tip, de-stained and in-gel digested as described [49] with some
modifications. Briefly, the spots were de-stained using 50 mM
NH4HCO3 in 50% acetonitrile and dried in a Speed Vac
concentrator. The protein was then digested by incubation
overnight at 37uC with sequencing grade trypsin (Promega,
Madison, WI, USA) in 50 mM NH4HCO3, pH 7.8. The
resulting peptides were extracted sequentially with 100 mlo f1 %
TFA and 100 ml of 0.1% TFA/60% acetonitrile and the combined
extracts lyophilized, re-suspended in 10ml of 5% acetonitrile in
0.5% formic acid. Tryptic digest samples were loaded onto a C18
pre-concentration column (5 mm6250 um, PepMap C18, LC
Packings, Amsterdam, Netherlands), and the peptides separated
on a reverse phase nano-column (15 cm675 cm, LC Packings).
Peptide separation was performed using a 60-minute linear
gradient of 5 to 95% acetonitrile in 0.5% formic acid at a flow
rate of 200 ml/min. Peptides were characterized using a Qstar XL
Q-TOF mass spectrometer (Applied Biosystems). For protein
identification, the peaklist-generating software was mascot.d11
version 1.6b23 of Analyst
RQSv1.1 build 9865, with the default
parameter, in Mascot MS/MS Ions Search version 2.1.04 (Mascot
Daemon, Matrix Science) using trypsin for enzyme specificity /
permission of 2 missed cleavages / variable modification of
carbmidomethyl (C) and oxidation (M) / 0.3 Da of mass tolerance
for precursor ions and 0.5 Da of mass tolerance for fragment ions;
the search against the Swissport protein database (NCBInr
2006.01.20) covered 6555851 sequences of the Homo sapiens subset,
with Mascot score larger than 50 as the cut-off score/expectation
value for accepting individual MS/MS spectrum. As our dataset
was small, no estimation of false positive rate or redundancy of
peptide matching multiple members of a protein family was
performed. Individual proteins identified by the search, particu-
larly the SF2/ASF phosphoprotein isoforms, were verified by
specific immunoblot (western) analysis.
Sample preparation and hybridization on Affymetrix
Exon Chip
We used the RNeasy Mini kit (Qiagen Inc., USA) to isolate total
RNA according to the manufacturer’s instructions and verified the
RNA quality by using RNA 6000 NanoAssay on an 2100
Bioanalyzer (Agilent). Two mg of total RNA, labeled according to
the GeneChipH Whole Transcript Sense Target Labeling Assay
manual of the manufacturer (Affymetrix) was hybridized to Human
Exon 1.0 ST Arrays (Affymetrix) for 16 hours at 45uC. The
hybridized arrays were washed and stained on a GeneChip Fluidics
Station 450 and scanned on a GCS3000 Scanner (Affymetrix).
Microarray data normalization
The values of the hybridized probesets were normalized and
analyzed for gene expression using dChip2006 software (http://
biosun1.harvard.edu/ ˜cli/dchip2006. exe). The GeneChipH Hu-
man Exon 1.0 ST microarray system has only perfect match
probes, but no mismatch (MM) probes available to perform data
normalization. Instead of the MM probes, we inferred and
removed the existing systematic biases based on the observed
intensities of the background probes (BGP) that were pre-designed
by Affymetrix. The raw data have been deposited in a MIAME
compliant database (GEO accession number #GSE24581).
Pre-processing and finding putative AS events from Exon
Chip
Single probe set mappings were performed over NCBI RefSeqs
and the exon-intron genomic coordinates of each known human
transcript were downloaded from UCSC Table Browser version
hg18 [50]. We applied three criteria to filter the putative AS events
from the exon chip. First, Pearson’s correlation coefficient was used
to compare the gene expression profiles between control and
amiloridesamples.Secondandthird,weused thenormalized values
of array intensities of exon expression for calculating the splicing
index, as previously described[51], and also for obtaining the log2
ratio. The 3 criteria are combined to filter the putative AS events.
Identification of over-represented GO Terms
We used the Gene Ontology (GO) resource of the database
DAVID [52] to identify common functions shared by genes
identified by high-throughput gene expression methods. The
hypergeometric test [53] was applied to calculate the significance
of enrichment (P) for a given over-representation GO category by
P~1{
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M
i
  
N{M
n{i
  
N
i
   , where N is the total number of genes
in the background distribution, M is the number of genes within
the distribution that are annotated to the node of interest, n is the
size of the list of interesting genes and K is the number of genes
within that list which are annotated to the node.
Computational analysis of regulatory factors in AS
mechanisms
The sequences within the alternatively spliced exon and its
flanking 59 and 39 introns werer analyzed for deciphering the
regulatory mechanisms of AS. The motif discovery tool,
MEME[54], was employed to search for motif sequences related
to the SR proteins and other regulatory factors of the AS
mechanisms. The DNA motifs discovered in the genes showing
modified RNA AS were listed according to the intronic or exonic
regions and the consensus nucleotide sequence patterns or position
matrices for data storage and analysis. A nucleotide sequence logo
[55] was created for each motif by alignment of multiple consensus
and consensus-like sequences to provide a more detailed precise
description than a consensus sequence of the binding site of a
regulatory factor involved in the modified AS.
Multi-color fluorocytometry
Cells treated with or without amiloride were collected at
v a r i o u st i m ei n t e r v a l sa n dw a s h e do n c ew i t hc o l dP B Sb y
centrifugation (300 xg for 5 min at 4uC). The harvested cells
were incubated in 0.05 ml of PBS containing an APC-labeled
monoclonal antibody, CD133/Prominin (BD Pharmingen
U S A ) ,f o r3 0 m i ni nt h ed a r ka n dt h e na d d e df l u o r e s c e i n -
labeled annexinV and propidium iodide for another 30 min of
incubation. After washing once with cold PBS, the triply stained
cells were analyzed in a flow fluorocytometer with BD
FACSDiVa software (BD Biosciences) to distinguish and
quantify the bound fluorescent antibody, the propidium-stained
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simultaneous measurement of apoptosis and cellular DNA
content, cells incubated with FITC-labeled annexinV were
washed, suspended and fixed in 70% ethanol at 220uCf o r3h r .
The fixed cells were precipitated, washed, and stained in 10
mg/ml propidium iodide and 0.2 mg/ml ribonuclease (Sigma
Co.). The bound annexinV and propidium-labeled DNA
content of individual cells were analyzed for apoptosis and cell
cycle effects by flow fluorocytometry.
Confocal and light microscopy of cytokinesis
Mitotic cells shaken off the rapidly growing monolayer
cultures were pelleted by centrifugation, suspended at
1.5x104/ml in growth medium with or without amiloride and
plated on 6-well dishes or 4-chamber glass slide dishes (1-ml per
well or chamber). After 24, 48 and 72 hours of incubation, the
cells were fixed in 2% paraformadehyde at 4uCo v e r n i g h ta n d
rinsed several times with cold PBS. For examination of actin-
associated cytoskeleton, cells on slide chambers were permea-
lized with 0.1% triton X-100/0.1 % BSA in PBS, stained with
FITC-labeled phalloidin (1 mg/ml) and DAPI (0.1 mg/ml) in
PBS and examined under fluorescent microscopy. Confocal cell
images were taken with a Leica CCD camera using Leica Image
manager 50 software. For light microscopic observation of post-
mitotic cytokinesis, paraformaldehyde-fixed PBS-washed cells
on 6-well dishes were rinsed with 50% methanol and 100%
methanol before Wright-Giemsa staining. Cell images were
recorded by a digital camera (DP70) equipped on an inverted
microscope (Olympus). The distance between two daughter
nuclei was measured manually using equally magnified images
on computer screen or hard-copy prints. The average and
standard deviation was calculated from data of more than 10
individual cells (dividing or divided) per sample to analyze the
cytokinetic migration.
Supporting Information
Figure S1 Effects of PI3K pathway inhibitors on SF2/
ASF and isoforms of HIPK3 and BCL-X in Huh-7 cells.
(TIF)
Figure S2 Inhibitory effects of amiloride treatment on
CD133 expression and clonogenicity of Huh-7 cells.
(TIF)
Figure S3 Cytotoxic and growth inhibitory effects of
amiloride on various human cancer leukemia and
normal cells in vitro.
(TIF)
Figure S4 Characterization of common genes subject to
amiloride modulation of RNA alternative splicing in
three human neoplastic cell lines.
(TIF)
Table S1 Top scoring candidate gene transcripts show-
ing amiloride-altered alternative splicing in Huh-7 cells.
The raw data have been deposited in a MIAME
compliant database (GEO accession number
#GSE24581).
(PDF)
Table S2 The significant GO terms of genes with
alternative RNA splicing altered in amiloride-treated
Huh-7 cells.
(PDF)
Table S3 The splicing factor-binding exonic and intro-
nic elements of genes showing altered alternative RNA
splicing in amiloride-treated Huh-7 cells.
(PDF)
Acknowledgments
We thank T. S. Lin for technical assistance in the early aspects of this
project.
Author Contributions
Concept formulation and research scheme: WKY JGC DMY. Proteomic
analysis: LPC. Western blots/RT-PCR/genomic arrays/exon arrays:
WHC YSC HHL WLC JGC. Bioinformatics and array data analysis:
WLC HDH. Functional cell biology experiments/fluorocytometric anal-
ysis: DMY WKY CHH. Thanks for the editorial assistance. Cell lines/
reagents/materials/analytic tools: WKY JGC LPC DMY HDH. Writing
the manuscript: WKY JGC.
References
1. Maniatis T, Tasic B (2002) Alternative pre-mRNA splicing and proteome
expansion in metazoans. Nature 418: 236–243.
2. Stetefeld J, Ruegg MA (2005) Structural and functional diversity generated by
alternative mRNA splicing. Trends Biochem Sci 30: 515–521.
3. Black DL (2003) Mechanisms of alternative pre-messenger RNA splicing. Annu
Rev Biochem 72: 291–336.
4. Matlin AJ, Clark F, Smith CW (2005) Understanding alternative splicing:
towards a cellular code. Nat Rev Mol Cell Biol 6: 386–398.
5. Fu XD (1995) The superfamily of arginine/serine-rich splicing factors. RNA 1:
663–680.
6. Hertel KJ, Graveley BR (2005) RS domains contact the pre-mRNA throughout
spliceosome assembly. Trends Biochem Sci 30: 115–118.
7. Pozzoli U, Sironi M (2005) Silencers regulate both constitutive and alternative
splicing events in mammals. Cell Mol Life Sci 62: 1579–1604.
8. Schwerk C, Schulze-Osthoff K (2005) Regulation of apoptosis by alternative pre-
mRNA splicing. Mol Cell 19: 1–13.
9. Stamm S, Ben-Ari S, Rafalska I, Tang Y, Zhang Z, et al. (2005) Function of
alternative splicing. Gene 344: 1–20.
10. Caceres JF, Kornblihtt AR (2002) Alternative splicing: multiple control
mechanisms and involvement in human disease. Trends Genet 18: 186–193.
11. PajaresMJ,EzpondaT,CatenaR,CalvoA,PioR,etal.(2007)Alternativesplicing:
an emerging topic in molecular and clinical oncology. Lancet Oncol 8: 349–357.
12. Srebrow A, Kornblihtt AR (2006) The connection between splicing and cancer.
J Cell Sci 119: 2635–2641.
13. Venables JP (2006) Unbalanced alternative splicing and its significance in
cancer. Bioessays 28: 378–386.
14. Wang GS, Cooper TA (2007) Splicing in disease: disruption of the splicing code
and the decoding machinery. Nat Rev Genet 8: 749–761.
15. Takehara T, Liu X, Fujimoto J, Friedman SL, Takahashi H (2001) Expression
and role of Bcl-xL in human hepatocellular carcinomas. Hepatology 34: 55–
61.
16. Curtin JF, Cotter TG (2004) JNK regulates HIPK3 expression and promotes
resistance to Fas-mediated apoptosis in DU 145 prostate carcinoma cells. J Biol
Chem 279: 17090–17100.
17. Bardella C, Costa B, Maggiora P, Patane S, Olivero M, et al. (2004) Truncated
RON tyrosine kinase drives tumor cell progression and abrogates cell-cell adhesion
through E-cadherin transcriptional repression. Cancer Res 64: 5154–5161.
18. Chen Q, Seol DW, Carr B, Zarnegar R (1997) Co-expression and regulation of
Met and Ron proto-oncogenes in human hepatocellular carcinoma tissues and
cell lines. Hepatology 26: 59–66.
19. Yuo CY, Lin HH, Chang YS, Yang WK, Chang JG (2008) 5-(N-ethyl-N-
isopropyl)-amiloride enhances SMN2 exon 7 inclusion and protein expression in
spinal muscular atrophy cells. Ann Neurol 63: 26–34.
20. Ghigna C, Giordano S, Shen H, Benvenuto F, Castiglioni F, et al. (2005) Cell
motility is controlled by SF2/ASF through alternative splicing of the Ron
protooncogene. Mol Cell 20: 881–890.
21. Cao W, Jamison SF, Garcia-Blanco MA (1997) Both phosphorylation and
dephosphorylation of ASF/SF2 are required for pre-mRNA splicing in vitro.
RNA 3: 1456–1467.
22. Kim KM, Lee YJ (2005) Amiloride augments TRAIL-induced apoptotic death
by inhibiting phosphorylation of kinases and phosphatases associated with the
P13K-Akt pathway. Oncogene 24: 355–366.
Modulating Oncogenic RNA Splicing
PLoS ONE | www.plosone.org 12 June 2011 | Volume 6 | Issue 6 | e1864323. Koizumi J, Okamoto Y, Onogi H, Mayeda A, Krainer AR, et al. (1999) The
subcellular localization of SF2/ASF is regulated by direct interaction with SR
protein kinases (SRPKs). J Biol Chem 274: 11125–11131.
24. Blaustein M, Pelisch F, Tanos T, Munoz MJ, Wengier D, et al. (2005) Concerted
regulation of nuclear and cytoplasmic activities of SR proteins by AKT. Nat
Struct Mol Biol 12: 1037–1044.
25. Cardinali B, Cohen PT, Lamond AI (1994) Protein phosphatase 1 can modulate
alternative 59 splice site selection in a HeLa splicing extract. FEBS Lett 352:
276–280.
26. Misteli T, Spector DL (1996) Serine/threonine phosphatase 1 modulates the
subnuclear distribution of pre-mRNA splicing factors. Mol Biol Cell 7:
1559–1572.
27. Patel NA, Kaneko S, Apostolatos HS, Bae SS, Watson JE, et al. (2005)
Molecular and genetic studies imply Akt-mediated signaling promotes protein
kinase C beta II alternative splicing via phosphorylation of serine/arginine-rich
splicing factor SRp40. Journal of Biological Chemistry 280: 14302–14309.
28. Pelisch F, Blaustein M, Kornblihtt AR, Srebrow A (2005) Cross-talk between
signaling pathways regulates alternative splicing - A novel role for JNK. Journal
of Biological Chemistry 280: 25461–25469.
29. Huang Y, Yario TA, Steitz JA (2004) A molecular link between SR protein
dephosphorylation and mRNA export. Proc Natl Acad Sci U S A 101:
9666–9670.
30. Medhurst AL, Laghmani EH, Steltenpool J, Ferrer M, Fontaine C, et al. (2006)
Evidence for subcomplexes in the Fanconi anemia pathway. Blood 108:
2072–2080.
31. Xiao SH, Manley JL (1997) Phosphorylation of the ASF/SF2 RS domain affects
both protein-protein and protein-RNA interactions and is necessary for splicing.
Genes Dev 11: 334–344.
32. Ngo JCK, Giang K, Chakrabarti S, Ma CT, Huynh N, et al. (2008) A sliding
docking interaction is essential for sequential and processive phosphorylation of
an SR protein by SRPK1. Molecular Cell 29: 563–576.
33. Skop AR, Liu HB, Yates J, Meyer BJ, Heald R (2004) Dissection of the
mammalian midbody proteome reveals conserved cytokinesis mechanisms.
Science 305: 61–66.
34. Suetsugi A, Nagaki M, Aoki H, Motohashi T, Kunisada T, et al. (2006)
Characterization of CD133(+) hepatocellular carcinoma cells as cancer stem/
progenitor cells. Biochemical and Biophysical Research Communications 351:
820–824.
35. Chang WH, Liu TC, Yang WK, Lee CC, Lin YH, et al. Amiloride modulates
alternative splicing in leukemic cells and resensitizes Bcr-AblT315I mutant cells
to imatinib. Cancer Res 71: 383–392.
36. Bull MB, Laragh JH (1968) Amiloride. A potassium-sparing natriuretic agent.
Circulation 37: 45–53.
37. Swift PA, MacGregor GA (2004) The epithelial sodium channel in hypertension:
genetic heterogeneity and implications for treatment with amiloride.
Am J Pharmacogenomics 4: 161–168.
38. Yun CY, Velazquez-Dones AL, Lyman SK, Fu XD (2003) Phosphorylation-
dependent and -independent nuclear import of RS domain-containing splicing
factors and regulators. Journal of Biological Chemistry 278: 18050–18055.
39. Prasad J, Colwill K, Pawson T, Manley JL (1999) The protein kinase Clk/Sty
directly modulates SR protein activity: both hyper- and hypophosphorylation
inhibit splicing. Mol Cell Biol 19: 6991–7000.
40. Gui JF, Lane WS, Fu XD (1994) A serine kinase regulates intracellular
localization of splicing factors in the cell cycle. Nature 369: 678–682.
41. Davis RJ, Czech MP (1985) Amiloride directly inhibits growth factor receptor
tyrosine kinase activity. Journal of Biological Chemistry 260: 2543–2551.
42. Johnson JM, Castle J, Garrett-Engele P, Kan Z, Loerch PM, et al. (2003)
Genome-wide survey of human alternative pre-mRNA splicing with exon
junction microarrays. Science 302: 2141–2144.
43. Ben-Dov C, Hartmann B, Lundgren J, Valcarcel J (2008) Genome-wide analysis
of alternative pre-mRNA splicing. Journal of Biological Chemistry 283:
1229–1233.
44. Chen WS, Wei SJ, Liu JM, Hsiao M, Kou-Lin J, et al. (2001) Tumor
invasiveness and liver metastasis of colon cancer cells correlated with
cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2-selective
inhibitor, etodolac. Int J Cancer 91: 894–899.
45. Juang SH, Wei SJ, Hung YM, Hsu CY, Yang DM, et al. (2004) IFN-beta
induces caspase-mediated apoptosis by disrupting mitochondria in human
advanced stage colon cancer cell lines. J Interferon Cytokine Res 24: 231–243.
46. Lozzio BB, Lozzio CB (1977) Properties of the K562 cell line derived from a
patient with chronic myeloid leukemia. Int J Cancer 19: 136.
47. Harn HJ, Lee HS, Ho LI, Lee WH, Ding JH (1994) Selective expression of
CD44 messenger RNA splice variants in four high grade human brain tumour
cell lines. Biochem Mol Biol Int 33: 743–749.
48. Hung SC, Yang DM, Chang CF, Lin RJ, Wang JS, et al. (2004) Immortalization
without neoplastic transformation of human mesenchymal stem cells by
transduction with HPV16 E6/E7 genes. Int J Cancer 110: 313–319.
49. Chan CH, Ko CC, Chang JG, Chen SF, Wu MS, et al. (2006) Subcellular and
functional proteomic analysis of the cellular responses induced by Helicobacter
pylori. Mol Cell Proteomics 5: 702–713.
50. Karolchik D, Hinrichs AS, Furey TS, Roskin KM, Sugnet CW, et al. (2004) The
UCSC Table Browser data retrieval tool. Nucleic Acids Res 32: D493–496.
51. Srinivasan K, Shiue L, Hayes JD, Centers R, Fitzwater S, et al. (2005) Detection
and measurement of alternative splicing using splicing-sensitive microarrays.
Methods 37: 345–359.
52. Dennis G, Jr., Sherman BT, Hosack DA, Yang J, Gao W, et al. (2003) DAVID:
Database for Annotation, Visualization, and Integrated Discovery. Genome Biol
4: P3.
53. Boyle EI, Weng S, Gollub J, Jin H, Botstein D, et al. (2004) GO::TermFinder--
open source software for accessing Gene Ontology information and finding
significantly enriched Gene Ontology terms associated with a list of genes.
Bioinformatics 20: 3710–3715.
54. Bailey TL, Williams N, Misleh C, Li WW (2006) MEME: discovering and
analyzing DNA and protein sequence motifs. Nucleic Acids Res 34: W369–373.
55. Crooks GE, Hon G, Chandonia JM, Brenner SE (2004) WebLogo: a sequence
logo generator. Genome Res 14: 1188–1190.
Modulating Oncogenic RNA Splicing
PLoS ONE | www.plosone.org 13 June 2011 | Volume 6 | Issue 6 | e18643